Drug Profile
Upamostat - Link Health Group/RedHill Biopharma
Alternative Names: Mesupron; RHB-107; WX-671Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Wilex
- Developer Heidelberg Pharma AG; Link Health Group; RedHill Biopharma; WILEX AG
- Class Amines; Antineoplastics; Antivirals; Imides; Piperazines; Small molecules; Sulfonamides
- Mechanism of Action Serine endopeptidase inhibitors; Urokinase-type plasminogen activator inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Phase II Breast cancer; Pancreatic cancer
- Clinical Phase Unknown Gastrointestinal disorders
- Preclinical Cholangiocarcinoma; Ebola virus infections; Influenza virus infections
- No development reported Cancer; Solid tumours
- Discontinued Head and neck cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (PO, Capsule)
- 02 Aug 2023 RedHill plans a phase III external non-dilutive funding trial for COVID 2019 infections US, Thailand, Ivory Coast, South Africa and Uganda
- 31 Jul 2023 Redhill Biopharma receives FDA clearance to start phase II trial